How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?
https://www.zacks.com/stock/news/2324368/how-should-you-play-pfizer-pfe-after-covid-flu-shot-setback?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2324368
Aug 20, 2024 - After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.
0
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
https://www.fool.com/investing/2024/08/18/forget-mounjaro-eli-lillys-next-big-blockbuster-ha/?source=iedfolrf0000001
Aug 18, 2024 - Eli Lilly has a lot going for it.
0
Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?
https://www.zacks.com/stock/news/2321929/is-eli-lilly-lly-a-buy-post-stellar-q2-earnings-raised-view?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2321929
Aug 14, 2024 - Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.
0
Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss
https://www.zacks.com/stock/news/2321469/here-s-how-to-play-novo-nordisk-nvo-after-q2-earnings-miss?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2321469
Aug 13, 2024 - Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.
0
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
https://www.zacks.com/stock/news/2321302/why-novo-nordisk-nvo-is-a-top-growth-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_growth_score-2321302
Aug 13, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock
https://www.fool.com/investing/2024/08/13/this-1-piece-good-news-for-eli-lilly-is-bad-news-f/?source=iedfolrf0000001
Aug 13, 2024 - A company's investments can easily ruin the plans of its competitors.
0
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates
https://www.zacks.com/stock/news/2319903/pharma-stock-roundup-lly-nvo-bayry-q2-earnings-mrk-s-new-deal-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2319903
Aug 09, 2024 - Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.
0
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
https://www.fool.com/investing/2024/08/09/prediction-this-weight-loss-stock-will-be-acquired/?source=iedfolrf0000001
Aug 09, 2024 - Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
0
Eli Lilly: The Next $1 Trillion Market Cap Stock?
https://www.zacks.com/commentary/2319475/eli-lilly-the-next-1-trillion-market-cap-stock?cid=CS-ZC-FT-investment_ideas-2319475
Aug 08, 2024 - Eli Lilly showcased the exceptional strength of its business during its quarterly earnings meeting on Thursday morning
0
Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug
https://www.fool.com/investing/2024/08/03/eli-lilly-vs-novo-nordisk-a-recent-study-suggests/?source=iedfolrf0000001
Aug 03, 2024 - These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market.
0